Stockreport

Pfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma

Pfizer, Inc.  (PFE) 
Last pfizer, inc. earnings: 4/28 06:45 am Check Earnings Report
PDF Primary endpoint met at the interim analysis in MagnetisMM-5 trial demonstrating a statistically significant and clinically meaningful improvement in progression-free su [Read more]